We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Nice to have

10 January 2011 By Robert Cyran

Buying the $10 bln UK orthopedic company would give the U.S. conglomerate scale to push back against larger hospital chains. It would also be an attractive use of cash stuck overseas. But J&J may heed potential antitrust concerns and its own history of financial discipline.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)